Insulet Corporation announced that its Omnipod 5 Automated Insulin Delivery (AID) System is now compatible with Abbott’s FreeStyle Libre 2 Plus continuous glucose monitoring (CGM) sensor in the U.S. This integration makes Omnipod 5 the most connected tubeless AID system in the U.S.
The compatibility allows millions of Americans who take insulin the ability to begin Pod therapy using their preferred CGM sensor. This broadens the appeal of Omnipod 5 to a wider patient population.
Expanding sensor compatibility increases the appeal and accessibility of the Omnipod 5 system to a broader patient population. This strategic move enhances Insulet's competitive advantage by offering greater choice and flexibility, potentially driving higher adoption rates and strengthening its market leadership in automated insulin delivery.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.